Investing.com -- U.S. President Donald Trump’s recent executive order on drug pricing could potentially jeopardize Swiss pharmaceutical company Roche’s planned $50 billion investment in the United States. Roche, listed as ROG.S, expressed this concern on Wednesday.

The executive order, signed by President Trump on Monday, instructs pharmaceutical firms to reduce the prices of brand-name drugs to match those in other affluent countries. However, several analysts and legal professionals have voiced that implementing such a policy might pose significant challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.